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Abstract
Low plasma CsA concentrations (<300–350 ng/mL) early following allogeneic hematopoi-
etic stem cell transplantation (HSCT) is associated with an increased risk of developing
acute graft-versus-host disease (aGvHD). Nevertheless, the current optimal target trough
concentration for CsA following HSCT is considered to be 200–400 ng/mL. Here, we per-
formed a retrospective analysis of a homogeneous group of 129 patients who received
HSCT after non-myeloablative conditioning, and we analyzed the impact of CsA trough con-
centration measured during the first four weeks (CsA W1-4) on the incidence aGvHD,
relapse-free survival (RFS), non-relapse mortality (NRM), overall survival (OS), and toxicity.
The 180-day incidence of grade II-IV aGvHD was 25% (32/129 patients). In multivariate
analysis the incidence of grade II-IV aGvHD was significantly lower among patients with a
CsA W1-4 concentration�350 ng/mL compared to patients with a concentration <350 ng/
mL (18% versus 38%, respectively; P = 0.007), with a hazard ration (HR) of 0.38 (95% CI:
0.19–0.77). In contrast, we found no correlation between CsA trough concentration and
RFS, NRM, or OS. Moreover, we found an increased incidence of hypomagnesemia at
higher CsA concentrations, but no difference in the incidence of acute renal toxicity, hepatic
toxicity, or electrolyte imbalance. Interestingly, 30% of patients experienced hyponatremia
with no apparent cause other than the use of CsA, with urinalysis suggesting SIADH as the
underlying cause. Our findings suggest that a CsA trough concentration of 350–500 ng/mL
might be more appropriate in the first month following non-myeloablative HSCT.
Introduction
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative
treatment for many hematological malignancies, it is generally associated with significant early
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post-transplant complications, including acute graft-versus-host disease (aGvHD), which con-
tribute to non-relapse mortality (NRM)[1–4]. A variety of patient- and treatment-related fac-
tors can affect the incidence of these complications and include patient age, comorbidity,
conditioning intensity, and the use of T cell depletion therapy. In addition, post-HSCT
patients receive multiple drugs that cause side effects. Notably, the calcineurin inhibitors cyclo-
sporine A (CsA) and tacrolimus (TAC), which are commonly used to prevent GvHD, can
cause acute renal failure, hyperbilirubinemia, and electrolyte imbalances.
Calcineurin inhibitor–based regimens are widely used and are currently considered the
backbone of GvHD prophylaxis[5]. Despite the common use of these agents, the incidence of
grade II-IV aGvHD among patients is approximately 40–60%. Several dosing schemes have
been developed in an attempt to customize the intensity and duration of post-transplant
immunosuppression in order to match the anticipated risks of GvHD and disease relapse. His-
torically, the ideal target trough concentration of CsA in the plasma following HSCT was 200–
400 ng/mL [6–8], however, in a more recent EBMT-ELN guideline, achieving a trough con-
centration between 200–300 ng/mL was advised in order to prevent aGvHD early after HSCT
[9]. As for side effects, a concentration up to 500 ng/mL is presumed to be safe, despite a lack
of clear evidence to support this assumption[10, 11]. Low plasma concentrations of CsA and
TAC—particularly in the first weeks following HSCT—have consistently been associated with
a higher risk of developing GvHD[12–16]; therefore, trough concentration–based dosing has
become relatively common following HSCT. Importantly, however, in most of the above-men-
tioned studies, the risk of aGvHD was consistently higher in patients with a CsA concentration
well below 300–350 ng/mL, suggesting that the lower limit of 200 ng/mL may not be optimal.
In addition, limited data is available regarding the correlation between CsA concentration and
HSCT-associated toxicity and outcomes other than aGvHD[12, 16, 17].
Here, we examined the correlation between the CsA concentration in the first month fol-
lowing HSCT and the incidence of early complications and outcome in a homogenous cohort
of patients who received HSCT following non-myeloablative conditioning (NMA). Specifi-
cally, our goal was to determine whether current target concentrations are optimal in clinical
practice, and whether adjusting these targets is warranted in order to improve outcome and
reduce the risk of aGvHD in this patient population.
Patients and methods
Patients. We performed a single-center retrospective analysis of 129 out of 140 consecu-
tive patients who received an allogeneic HSCT from January 2013 through August 2017 fol-
lowing NMA conditioning for a hematological malignancy. At the time of treatment, all
patients provided informed consent for the prospective collection of data and samples for
investigational use. This retrospective study was approved by the Institutional Review Board at
Radboud University Nijmegen Medical Center.
The characteristics and features of the patients, donors, and HSCT procedures are summa-
rized in Table 1.
Conditioning and post-HSCT immunosuppression. All patients received Flu-TBI con-
ditioning consisting of 30 mg/m2 fludarabine on days -4, -3, and -2, and low-dose TBI (2 Gy)
on day -1 (days are expressed relative to transplantation)[10, 18–20]. In the case of a mis-
matched unrelated donor (MMUD), the patient also underwent in vivo T cell depletion with 2
mg/kg/day Thymoglobulin (rabbit-ATG; Genzyme) on days -8, -7, -6, and -5. In accordance
with study protocols (NCT02252107), patients with an adverse risk of developing myeloid
malignancies also received 10 days of decitabine (Figure A in S1 File)[21]. On day 0, all
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patients received a T cell–repleted graft with mobilized peripheral blood stem cells or bone
marrow stem cells.
Post-HSCT immunosuppression included mycophenolate mofetil for 28 or 96 days for
matched related donors (MRDs) and unrelated donors (both matched and mismatched),
respectively, and oral CsA for 180 days. CsA was initially dosed at 4.5 mg/kg twice daily, and
the dose could be adjusted in the event of clinical toxicity or in the event that a suboptimal
and/or toxic CsA concentration was achieved. In the case of clinical toxicity, standard practice
employed at our institution is to omit one dose of CsA and reduce subsequent doses by 12.5–
25%.
Supportive care measures. Antimicrobial prophylaxis was according to current practice
(See S1 File). Ursodeoxycholic acid was not routinely used in our practice.
Definitions. As part of routine care at our medical center, CsA concentration was mea-
sured 4–5 days after the starting dose, at 12 hrs after the last administration. CsA concentration
Table 1. Patient, donor, and HCT procedure characteristics (N = 129 patients).
Characteristics
Patient age in years, median (range) 61 (20–75)
Age�55 years, N (%) 100 (78)
Male/Female 70/59
Diagnosis, N (%)
• AML 76 (59)
• High-risk MDS/CMML 25 (19)
• MM/PCL 13 (10)
• Other: NHL, CLL, aCML, ALL 15 (12)
Disease risk index, N (%)
• Low/Intermediate 40 (31)
• High/Very high 89 (69)
HCT-CI score, median, range 3 (0–8)
HCT-CI� 3 77 (60)
EBMT score, median, range 3 (1–6)
Conditioning regimen, N (%)
• Flu-TBI 65 (50)
• Decitabine-Flu-TBI 43 (33)
• ATG-Flu-TBI 14 (11)
• ATG-decitabine-Flu-TBI 7 (6)
Donor, N (%)
• MRD 35 (27)
• MUD 73 (56)
• MMUD 21 (17)
Stem cell source, peripheral blood, N (%) 123 (95)
CMV status patient, N (%)
• Negative 43 (34%)
• Positive 86 (66%)
CsA W1-4, median (range) (127.5–816.7)
CsA W1-4, mean value�350 ng/mL, N(%) 87 (67)
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic
leukemia; MM, multiple myeloma; PCL, plasma cell leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic
lymphocytic leukemia; aCML, atypical chronic myeloid leukemia; ALL, acyte lymphoblastic leukemia
https://doi.org/10.1371/journal.pone.0213913.t001
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was subsequently measured at least once weekly during the first 2–3 months using validated
ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS; Waters
Corporation, Milford, MA). The optimal target trough concentration of CsA was defined as
200–400 ng/mL in accordance with general recommendations[6–8]. Accordingly, CsA con-
centration was considered suboptimal at<200 ng/mL, high at�400 ng/mL, and potentially
toxic at�500 ng/mL[10, 11]. Changes to the dosing regimen were made at the discretion of
the treating HSCT physician. CsA trough concentrations measured in weeks 1 through 4 were
collected and used to calculate an average value for the entire 4-week period referred to hereaf-
ter as “CsA W1-4”. For our analysis, cut-off values were used at increments of 50 ng/mL based
on data published by Rogosheske et al.[15]
The disease risk index (DRI), HSCT comorbidity index (HSCT-CI), and European Group
for Blood and Marrow Transplantation (EBMT) risk score were determined in accordance
with published scoring systems[22–24].
Outpatient clinical and laboratory assessments were performed twice weekly during the
first month following HSCT, and subsequently once a week. Non-hematological adverse
events, including hyperbilirubinemia, electrolyte imbalances, and/or renal failure, were graded
in accordance with version 4 of the Common Terminology Criteria for Adverse Events
(CTCAE). Adverse events graded as�2 were considered to be clinically relevant.
Post-HSCT aGvHD was defined in accordance with the criteria proposed by Harris et al.
[25]. Clinically suspected cases of aGvHD were confirmed histologically. Classic aGVHD
occurs within and late onset aGvHD beyond the first 100 days post HSCT[26]. Late onset
aGvHD is a frequent occurrence with the Flu-TBI scheme due to relatively late initiation of cal-
cineurin inhibitors tapering (around day 100), therefore we evaluated aGvHD grade II-IV at
day 180 [10, 27]. Chronic GvHD (cGvHD) was scored and graded according to NIH guide-
lines[28]. Relapse of the hematological malignancy was classified in accordance with consensus
definitions and consisted almost entirely of hematological relapses (e.g., morphological
relapse)[29]. Early relapse was defined as relapse within 6 months of HSCT. The occurrence of
aGvHD, non-relapse mortality (NRM), relapse-free survival (RFS), and overall survival (OS)
were defined in accordance with EBMT statistical guidelines[30]. GvHD/relapse-free survival
(GRFS) was defined as survival without relapse, aGvHD grade III-IV or moderate-severe
cGvHD[31].
Statistical analysis. We used descriptive statistics to analyze the patient, donor, and
HSCT characteristics. To investigate possible risk factors associated with the occurrence of
grade II-IV aGvHD by day 180, relapse by day 180, moderate-severe cGvHD, and toxicity
(e.g., renal toxicity, hepatic toxicity, or an electrolyte imbalance), we first performed univariate
analyses; we then included any factors with a P-value�0.15 in a multivariate analysis using
logistic regression. For details on the factors included in the analysis see Tables A and B in S1
File. Since no significant differences were found between the MUD and MMUD subgroups for
all outcome measures we chose to merge this group in the analysis.
To examine the relationship between renal toxicity and CsA W1-4, we performed a Pear-
son’s correlation analysis between CsA W1-4 and the change in creatinine levels relative to
baseline (prior to conditioning).
We estimated the occurrence of aGvHD, NRM, RFS, GRFS and OS using the Kaplan-Meier
method.
Putative factors affecting the occurrence of GvHD, NRM, GRFS, RFS, and OS were selected
for univariate analysis, and any factors with a P-value�0.15 were then incorporated in a multi-
variate analysis using Cox regression. For details on the factors included in the analysis see
Tables A and B in S1 File.
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Differences with a P-value of<0.05 were considered statistically significant. SPSS Statistics
version 22.0 (IBM Corp., Armonk, NY) was used for statistical analyses.
Results
A total of 129 out of 140 consecutive patients were included in our final analysis. The mini-
mum follow-up period was 6 months, and data regarding the trough CsA concentration were
available for at least three separate weeks during the first month following HSCT. From the
original 140 consecutive patients, 11 patients were excluded due to the following reasons:
administration of intravenous CsA (4 patients), an early switch from CsA to TAC (4 patients;
2 switched due to posterior reversible encephalopathy syndrome), and insufficient data regard-
ing CsA concentration (3 patients).
CsA trough concentration
The median CsA trough concentration at 1, 2, 3, and 4 weeks following HSCT was 330, 380,
410, and 400 ng/mL, respectively (Fig 1). The median calculated concentration for the entire
4-week period (CsA W1-4) was 402 ng/mL (range: 127–816 ng/mL) and correlated strongly
with the CsA concentration during the first 2 weeks (CsA W1-2). Based on the predefined tar-
get range of 200–400 ng/mL, 4, 65, and 24 patients had a suboptimal concentrations (i.e., <200
ng/mL), a high concentration (i.e.,�400 ng/mL), or a potentially toxic concentration (i.e.,
�500 ng/mL), respectively.
Post-HSCT complications
Acute and chronic GvHD. In our patient cohort, the median interval between HSCT and
the onset of aGvHD (grade I through grade IV) was 60 days (range: 10–322 days). The 180-day
rate of grade II-IV and grade III-IV aGvHD was 25% (32/129 patients) and 10% (13/129
patients), respectively (Table 2). Based on a univariate analysis, the risk factors for developing
grade II-IV aGvHD were receipt of a graft from either a MUD or MMUD and a CsA W1-4
value <350 ng/mL (Table A in S1 File). A multivariate logistic regression analysis revealed that
both factors had a statistically significant impact with respect to increasing the risk of grade
II-IV aGvHD by day 180.
An analysis of the incidence of aGvHD over time using Kaplan-Meier and Cox regression
analysis revealed that both MUD/MMUD and a CsA W1-4 value�350 ng/mL had a signifi-
cant influence in both univariate and multivariate analyses (Table B in S1 File). The incidence
of aGvHD within the first 6 months was 18% (16/87) in patients with a CsA W1-4 value�350
ng/mL compared to 38% (16/42) in patients with a concentration <350 ng/mL, corresponding
to a hazard ratio (HR) of 0.38 (95% CI: 0.19–0.77; P = 0.007) (Fig 2). We performed the same
analysis for a cut-off value of 300 ng/mL, although there was a significant difference in aGvHD
incidence (P = 0.02), the group with levels < 300 ng/ml was too small to derive any conclu-
sions. Nevertheless, this suggests that trough concentrations above 300 ng/mL are acceptable.
Moderate-severe cGvHD occurred in 28% (36/129) of patients. Multivariate logistic regres-
sion analysis revealed that a HSCT with a (M)MUD increased and the use of ATG reduced the
risk for cGvHD (HR 4.30; 95% CI: 1.45–12.77; P = 0.007, and HR 0.33; 0.38; 95% CI: 0.19–
0.77; P = 0.03)). No difference was seen in the incidence of cGvHD between patients with CsA
W1-4 value< or�350 ng/mL (33.3% versus 25%; P = 0.42).
Infection. No impact of CsA trough levels was seen on CMV infection and disease
(Table A in S1 File).
Acute renal toxicity. Renal toxicity was relatively common among patients in our cohort
who received high-dose CsA. Specifically, 49% (63/129) and 7.5% (10/129) of patients
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developed grade 2 (creatinine 2–3 times above baseline) or grade 3 (>3 times above baseline)
renal toxicity (Table 2). Consistent with renal toxicity, creatinine levels began to rise gradually
from the day of HSCT, reaching 125% of baseline at a median of 20 days (range: 6–42 days)
and peak levels on day 49 (range: 9–117 days). To our surprise, we found no significant associ-
ation between renal toxicity (i.e., grade�2) and CsA W1-4, and no other risk factors reached
statistical significance. We also found no significant correlation between CsA W1-4 and the
change in creatinine levels relative to baseline (R2 = 0.016) (Table A and Figure B in S1 File).
Hepatic toxicity. We observed two peaks in hyperbilirubinemia following HSCT. The
first peak occurred early at a median of 6 days after HSCT (range: 1–11) and appeared to coin-
cide with the start of CsA treatment. Grade 3 hyperbilirubinemia was present in 29% of
patients (38/129) and was often not accompanied by any other abnormal liver function tests.
In these 38 patients, the median bilirubin level was 68 μmol/L (range: 51–161 μmol/L), and the
hepatic toxicity resolved after the dose of CsA was adjusted. None of the cases of early
Fig 1. Summary of CsA trough concentration measured 1 to 4 weeks after HCT.
https://doi.org/10.1371/journal.pone.0213913.g001
Cyclosporine A concentrations and HCT outcome
PLOS ONE | https://doi.org/10.1371/journal.pone.0213913 March 21, 2019 6 / 15
hyperbilirubinemia were related to either GvHD or sinusoidal obstructive syndrome (SOS).
Patient age (i.e.,�60 years) was the only variable that was significantly associated with an
increased risk of hepatic toxicity (HR: 2.39; 95% CI: 1.03–5.54; P = 0.04) (Table A in S1 File).
The second peak in hyperbilirubinemia occurred after a median interval of 142 days and
was associated with the occurrence of aGvHD with liver involvement in 6% of cases. We found
no significant association between this second peak and increased CsA W1-4 concentration.
Electrolyte imbalance. Hypomagnesemia (a common side effect) developed in approxi-
mately half of our patients; specifically, 53% of patients (69/129) presented with grade 2 hypo-
magnesemia. In contrast, grade 2 hyperkalemia was relatively rare, occurring in only 6% (8/
129) of patients (Table 2). Hypomagnesemia developed relatively early, with a median onset of
7 days (range: 2–19 days). CsA W1-4 concentration was significantly associated with grade 2
Table 2. Post-HCT complications and outcome (N = 129).
Complication
Acute GvHD, N (%)
• Grade 0-I 91 (70)
• Grade II 22 (17)
• Grade III-IV 16 (13)
Acute GvHD grade II-IV day 180, N (%) 32 (25)
Acute GvHD grade III-IV day 180, N (%) 13 (10)
Primary graft failure, no (%) 5 (4%)
CMV infection or disease <3 months, N (%) 30/2 (23/1.5)
EBV infection/disease, N (%) 6/2 (4.5/1.5)
Early hyperbilirubinemia, grade 3, N (%) 38 (29)
Onset hyperbilirubinemia, median day (range)� 6 (1–11)
Acute kidney injury, grade 2, N (%) 63 (49)
Acute kidney injury, grade 2, N (%) 10 (8)
Creatinine change from baseline, median (range) x 2.0 (1.0–5.4)
Creatinine>25% BL, median day of onset (range)� 20 (6–42)
Electrolyte imbalance
• Hyperkalemia grade 2, N (%) 8 (6)
• Hypomagnesemia grade 2, N (%) 69 (53)
• Hyponatremia grade 3, N (%) 40 (31)
Relapse
• Total occurrence of relapse, N (%) 34 (26)
• Median day of onset relapse (range)� 159 (7–1224)
• Relapse at 6 months 19 (15%)
Mortality
• All-cause mortality 40 (32.5)
• All-cause mortality at 1 year, N (%) 25 (19)
• Non-relapse mortality, N (%) 22 (17)
• Non-relapse mortality at 1 year, N (%) 12 (9)
• Relapse-related mortality, N (%) 20 (15.5)
• Relapse-related mortality at 1 year, N (%) 13 (10)
Overall survival; at 1 year and 3 years 82% and 67%
Relapse-free survival; at 1 year and 3 years 70% and 54%
GvHD/relapse-free survival; at 1 year and 3 years 43% and 31%
�Relative to HCT, where HCT is day 0, and the start of CsA was on day -3.
https://doi.org/10.1371/journal.pone.0213913.t002
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hypomagnesemia, occurring in 59% and 34% of patients with a CsA W1-4 value�350 ng/mL
versus<350 ng/mL, respectively (HR: 2.95; 95% CI: 1. 37–6.33: P = 0.05) (Table A in S1 File).
In addition, hyponatremia was also a relatively common and early complication; 31% of
patients (40/129) developed grade 3 hyponatremia with a median onset of 11 days (range:
4–41 days) (Table 2). However, we found no association between CsA W1-4—or any other fac-
tor—and the occurrence of hyponatremia.
Additional urinalysis had been performed in 19 patients. In 7 of these patients, the apparent
cause of hyponatremia was identified and included the use of diuretics and the occurrence of
SIADH (syndrome of inappropriate antidiuretic hormone secretion) during an infection; in
these cases, the median onset of hyponatremia was relatively late (30 days after HSCT). In the
other 12 patients, the median onset of hyponatremia was 9 days after HSCT, and both urine
and plasma analyses revealed a pattern consistent with SIADH; specifically, the median plasma
sodium level was 125 mmol/L (range: 121–129 mmol/L), the median urine sodium level was
Fig 2. Cumulative prevalence of grade II-IV acute GvHD in patients with a trough CsA concentration<350 ng/mL (blue; N = 42) versus a
trough CsA concentration�350 ng/mL (green; N = 87).
https://doi.org/10.1371/journal.pone.0213913.g002
Cyclosporine A concentrations and HCT outcome
PLOS ONE | https://doi.org/10.1371/journal.pone.0213913 March 21, 2019 8 / 15
64 mmol/L (range: 44–164 mmol/L), the median plasma osmolality was 267 mOsmol/kg
(range: 259–274 mOsmol/kg), and the median urine osmolality was 454 mOsmol/kg (range:
227–654 mOsmol/kg).
Post-HSCT outcome. Relapse. Among our patient cohort, the rate of relapse was 26%
(34/129), occurring after a median delay of 159 days (range: 37–1224 days). Early relapse
(defined as occurring within 6 months of HSCT) occurred in 15% of all patients (19/129). Our
analysis revealed that both a diagnosis of AML/MDS and a high/very high DRI value were sig-
nificantly associated with an increased rate of relapse (Table A in S1 File).
NRM, RFS, GRFS and OS. The median follow-up of all 129 patients was 20.6 months
(range: 0.7–61.5 months), for patients alive the median follow up was 30.9 months (range: 7.0–
61.5). The overall mortality rate was 32.5% (45/129) and occurred after a median post-HSCT
interval of 244 days (range: 21–1127 days); relapse-related mortality (RRM) and non-relapse-
related mortality (NRM) occurred in 15.5% and 17% of patients, respectively (Table 2). The
overall survival (OS) rate at 1 and 3 years was 81% and 69%, respectively, the rate of relapse-
free RFS at 1 and 3 years was 70% and 54%, respectively, and the rate of GRFS at 1 and 3 years
was 43% and 31% (Table 2 and Fig 3).
No factors were significantly associated with NRM. However, a univariate analysis revealed
that both a diagnosis of AML/MDS and a high/very high DRI were associated with reduced
RFS and GRFS (Table B in S1 File). On multivariate analysis, only high/very high DRI
remained significantly associated with both reduced RFS and GRFS (HR: 2.74 and 2.05,
respectively; both P = 0.001) (Table B in S1 File). Also with respect to OS, a high/very high
DRI was the only significant factor identified by multivariate analysis (HR: 1.98; 95% CI: 1.12–
3.68; P = 0.02) (Table B in S1 File).
None of the cut-off values for CsA W1-4 were significantly associated with any of the sur-
vival outcomes, including NRM, RFS, GRFS and OS (Table B and Figures C and D in S1 File).
However, although not statistically significant, the 1-year the GRFS tended to be better in
patients with CsA W1-4�350 ng/mL versus <350 ng/mL (47% vs 38%).
Discussion
At our medical center, we historically used a target trough concentration of CsA of 200–400
ng/mL for allogeneic HSCT recipients following NMA conditioning, in accordance with estab-
lished guidelines[9]. Although this target is generally recommended, there is a striking paucity
of data supporting this target range; moreover, several studies showed a clear reduction in the
incidence of aGvHD among patients who have a higher trough concentration in the first few
weeks following HSCT[12–15]. In our study, more than 95% of patients had a CsA trough con-
centration >200 ng/mL, with a median CsA W1-4 value of 402.5 ng/mL. This suggests that
with respect to aGvHD prophylaxis, so-called “optimal” CsA dosing was achieved in virtually
all patients, at least based on current recommendations. Nevertheless, we found that achieving
a CsA W1-4 concentration�350 ng/mL significantly reduced the occurrence of grade II-IV
aGvHD within the first 6 months following HSCT. This protective effect was the most promi-
nent early after HSCT, as illustrated by the strong divergence in the occurrence of aGvHD and
OS after the first two months (see Figs 2 and 3). Similar results were reported by Malard et al.
[12]; their optimal CsA trough concentration was 348 ng/mL. Although this difference in opti-
mal concentration may be due in part to differences in the clinical settings and/or the cohort
composition, it suggests that a target CsA trough concentration of just�200 ng/mL is too low
for aGvHD prophylaxis. Our findings are also supported by a study by Rogosheske et al., who
showed that each 50 ng/mL increase in trough CsA concentration was associated with a 33%
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decrease in the relative risk of developing aGvHD[15]. In concordance with the aforemen-
tioned and previous studies, we found no effect of CsA levels on cGVHD[15, 32].
No significant correlation between CsA W1-4 concentration and any of the survival out-
comes measured was found. In an early study by Bacigalupo, a higher risk of relapse and
reduced disease-free survival was seen in patients who received a myeloablative conditioning
regimen and had higher median CsA levels in the first 2 weeks after transplant[33]. Surpris-
ingly, RFS did not differ between CsA W1-4 groups in our population. However, only a frac-
tion of our patients had CsA levels > 600ng/ml which was the median CsA level associated
with higher risk of relapse in that study. Despite having an apparently high impact on the risk
of aGvHD, in our cohort, NRM was also not influenced. This finding is in contrast with a
study by Ram et al., which found decreased risks of aGVHD NRM and overall mortality with a
higher CsA trough concentration in the first 2 weeks after transplantation. [17]. The absence
of such an effect in our study is likely related to the overall low rate of NRM (9% at 1 year)
and/or the relatively low rate of grade III-IV aGvHD (10%) in our cohort. Importantly, our
study concerned patients transplanted in more recent years (between 2013–2017 versus 2001–
2009), and changes in supportive care and aGvHD treatment might at least partially explain
this difference.
In our population, we found no clear correlation between CsA trough concentration and
the occurrence of either hepatic or renal toxicity. Although the incidence of hepatic and renal
toxicity was relatively high, it is similar to previous results reported for patients who received
Fig 3. Overall survival, relapse-free, and GvHD/relapse-free survival in the total cohort. Kaplan-Meier curves for OS (blue), RFS (red) and GRFS (green) are shown for
the entire cohort of 129 patients who received Flu-TBI–based non-myeloablative conditioning prior to HCT.
https://doi.org/10.1371/journal.pone.0213913.g003
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Flu-TBI–based conditioning[4, 18]. In addition, although CsA-related renal and hepatic toxic-
ity was shown to be dose-dependent in previous studies, particularly in kidney transplant
recipients[34, 35], we found no such effect in our cohort. One possible explanation might be
the relatively high starting dose of CsA (4.5 mg/kg twice daily) in our cohort; at these high dos-
ages, individual factors such as previous renal toxicity, concomitant drug use, and age likely
become more important factors in determining a patient’s susceptibility to develop toxicity.
For example, our finding that nearly 50% of patients in our cohort developed grade 2 renal tox-
icity may have been due—at least in part—to the relatively high median age of this cohort (61
years), given that the risk of nephrotoxicity increases with age[36].
Hyperbilirubinemia was an isolated finding that occurred early following HSCT and
resolved after the CsA dose was adjusted; none of these early cases were attributed to liver
GvHD or SOS. In vitro studies offer a possible explanation for this effect, showing that CsA
inhibits canalicular bile transport by inhibiting the bile salt export pump, resulting in cholesta-
sis and decreased bilirubin excretion[4, 37]. Moreover, the decrease in renal function may
have contributed to hyperbilirubinemia by reducing renal clearance of conjugated bilirubin.
A higher CsA concentration (i.e.,�350 ng/mL) was associated with the occurrence of hypo-
magnesemia. Although we found a statistically significant difference in magnesium concentra-
tion between patients with a CsA concentration >350 ng/mL compared to patients with a CsA
concentration <350 ng/mL, the overall rate of hypomagnesemia in our cohort was relatively
high. Thus, decreased magnesium reabsorption—with loss of renal magnesium due to tubulo-
pathy—is highly common among patients treated with CsA and appears to be concentration-
dependent[38]. Because of the limited clinical consequences associated with this side effect, we
believe that adjusting the dose of CsA based solely on the development of hypomagnesemia
may not be necessary.
A relatively high percentage of our patients (31%) developed grade 3 hyponatremia; this
finding is somewhat remarkable given that hyponatremia is usually considered to be related to
the use of TAC rather than CsA[39]. The mechanism by which calcineurin inhibitors induce
hyponatremia is poorly understood and appears to differ between CsA and TAC. For example,
TAC has been shown to increase renal sodium excretion and SIADH, both of which contribute
to hyponatremia in kidney transplant and allogeneic HSCT recipients[32, 39–41]. With
respect to CsA, although evidence argues against renal salt wasting, virtually no data exists
regarding the role of SIADH[41]. In our cohort, CsA was implicated as the cause of hyponatre-
mia, with urinalysis suggesting SIADH as the underlying mechanism of action. However, the
lack of urinalysis results for half of the patients with hyponatremia precludes any conclusions
regarding the possible relationship between hyponatremia and CsA. Additional studies are
needed in order to examine this putative association further and to test the hypothesis that
SIADH is the underlying mechanism of action.
Our study was limited by its retrospective nature and by the fact that it included patients
from a single medical center. Differences in the composition of patient cohorts among various
centers and/or studies can play a role in this type of analysis, thus preventing us from making
any general recommendations regarding CsA target values. Still, our finding that the rate of
aGvHD was lower among patients with a higher trough CsA concentration suggests that the
existing target range may be too low and that the optimal target CsA concentration should be
set to�350 ng/mL for the first month after transplantation. Importantly, in our relatively
older cohort of patients, this higher concentration was not associated with a clinically relevant
increased risk of toxicity or an increase in risk for relapse. At the very least, adjusting the CsA
merely based on exceeding the current upper limit of 400 ng/mL should be discouraged. In
addition, dose augmentation should be considered in patients with an early trough
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concentration below 300–350 ng/mL, particularly if there is no evidence of toxicity. Neverthe-
less, prospective data are needed in order to support our findings and recommendations.
In conclusion, we report a significant association between post-HSCT trough concentration
of CsA and the occurrence of aGvHD, and we report that trough CsA concentration is not
generally associated with common forms of post-HSCT toxicity. Our findings, supported by
previous studies suggest that 350–500 ng/mL is a more appropriate target concentration for
CsA trough levels in the first few weeks following HSCT, representing a paradigm shift from
the current recommendation of 200–400 ng/mL. This change in the target CsA trough concen-
tration is particularly relevant in the context of Flu-TBI–based NMA conditioning in which
GvHD prophylaxis includes an initial dosing regimen of oral CsA given at 4.5 mg/kg twice
daily.
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